Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats

Yin Ji Li, Akiko Kukita, Toshiyuki Watanabe, Toshio Takano, Pengfei Qu, Keisuke Sanematsu, Yuzo Ninomiya, Toshio Kukita

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO). In this study, we investigated the regulatory function of NDGA on inflammatory bone destruction mediated by osteoclasts. NDGA markedly inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced formation of osteoclasts in cultures of murine osteoclast precursor cell line RAW-D cells and primary bone marrow-derived macrophages culture systems. The inhibitory effect of NDGA on osteoclastogenesis did not arise from the inhibition of 5-LO activity. NDGA did not affect MAPKs, such as p38, JNK, and NF-κB, but significantly inhibited the induction of NFATc1, a key transcription factor for osteoclastogenesis. NDGA also suppressed activation of ERK in osteoclast precursors. RANKL-induced calcium oscillation observed in osteoclast precursors was completely diminished by the addition of NDGA. In mature osteoclasts, RANKL-induced nuclear translocation of NFATc1 was clearly inhibited by NDGA treatment. Finally, in vivo studies demonstrated that administration of NDGA significantly reduced severe bone destruction and osteoclast recruitment in the ankle joint of rats with adjuvant-induced arthritis. These results indicate the potential utility of NDGA as a therapeutic agent for ameliorating inflammatory bone destruction in rheumatoid arthritis.

Original languageEnglish
Pages (from-to)1777-1787
Number of pages11
JournalLaboratory Investigation
Volume92
Issue number12
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Masoprocol
Osteogenesis
Arthritis
Osteoclasts
Bone and Bones
Arachidonate 5-Lipoxygenase
Lipoxygenase Inhibitors
Experimental Arthritis
Calcium Signaling
Somatostatin-Secreting Cells
Ankle Joint
Cytoplasmic and Nuclear Receptors
Rheumatoid Arthritis
Transcription Factors
Macrophages

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats. / Li, Yin Ji; Kukita, Akiko; Watanabe, Toshiyuki; Takano, Toshio; Qu, Pengfei; Sanematsu, Keisuke; Ninomiya, Yuzo; Kukita, Toshio.

In: Laboratory Investigation, Vol. 92, No. 12, 01.12.2012, p. 1777-1787.

Research output: Contribution to journalArticle

Li, Yin Ji ; Kukita, Akiko ; Watanabe, Toshiyuki ; Takano, Toshio ; Qu, Pengfei ; Sanematsu, Keisuke ; Ninomiya, Yuzo ; Kukita, Toshio. / Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats. In: Laboratory Investigation. 2012 ; Vol. 92, No. 12. pp. 1777-1787.
@article{a5366ba4eeb34d09b59556a802a14717,
title = "Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats",
abstract = "Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO). In this study, we investigated the regulatory function of NDGA on inflammatory bone destruction mediated by osteoclasts. NDGA markedly inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced formation of osteoclasts in cultures of murine osteoclast precursor cell line RAW-D cells and primary bone marrow-derived macrophages culture systems. The inhibitory effect of NDGA on osteoclastogenesis did not arise from the inhibition of 5-LO activity. NDGA did not affect MAPKs, such as p38, JNK, and NF-κB, but significantly inhibited the induction of NFATc1, a key transcription factor for osteoclastogenesis. NDGA also suppressed activation of ERK in osteoclast precursors. RANKL-induced calcium oscillation observed in osteoclast precursors was completely diminished by the addition of NDGA. In mature osteoclasts, RANKL-induced nuclear translocation of NFATc1 was clearly inhibited by NDGA treatment. Finally, in vivo studies demonstrated that administration of NDGA significantly reduced severe bone destruction and osteoclast recruitment in the ankle joint of rats with adjuvant-induced arthritis. These results indicate the potential utility of NDGA as a therapeutic agent for ameliorating inflammatory bone destruction in rheumatoid arthritis.",
author = "Li, {Yin Ji} and Akiko Kukita and Toshiyuki Watanabe and Toshio Takano and Pengfei Qu and Keisuke Sanematsu and Yuzo Ninomiya and Toshio Kukita",
year = "2012",
month = "12",
day = "1",
doi = "10.1038/labinvest.2012.134",
language = "English",
volume = "92",
pages = "1777--1787",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats

AU - Li, Yin Ji

AU - Kukita, Akiko

AU - Watanabe, Toshiyuki

AU - Takano, Toshio

AU - Qu, Pengfei

AU - Sanematsu, Keisuke

AU - Ninomiya, Yuzo

AU - Kukita, Toshio

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO). In this study, we investigated the regulatory function of NDGA on inflammatory bone destruction mediated by osteoclasts. NDGA markedly inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced formation of osteoclasts in cultures of murine osteoclast precursor cell line RAW-D cells and primary bone marrow-derived macrophages culture systems. The inhibitory effect of NDGA on osteoclastogenesis did not arise from the inhibition of 5-LO activity. NDGA did not affect MAPKs, such as p38, JNK, and NF-κB, but significantly inhibited the induction of NFATc1, a key transcription factor for osteoclastogenesis. NDGA also suppressed activation of ERK in osteoclast precursors. RANKL-induced calcium oscillation observed in osteoclast precursors was completely diminished by the addition of NDGA. In mature osteoclasts, RANKL-induced nuclear translocation of NFATc1 was clearly inhibited by NDGA treatment. Finally, in vivo studies demonstrated that administration of NDGA significantly reduced severe bone destruction and osteoclast recruitment in the ankle joint of rats with adjuvant-induced arthritis. These results indicate the potential utility of NDGA as a therapeutic agent for ameliorating inflammatory bone destruction in rheumatoid arthritis.

AB - Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO). In this study, we investigated the regulatory function of NDGA on inflammatory bone destruction mediated by osteoclasts. NDGA markedly inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced formation of osteoclasts in cultures of murine osteoclast precursor cell line RAW-D cells and primary bone marrow-derived macrophages culture systems. The inhibitory effect of NDGA on osteoclastogenesis did not arise from the inhibition of 5-LO activity. NDGA did not affect MAPKs, such as p38, JNK, and NF-κB, but significantly inhibited the induction of NFATc1, a key transcription factor for osteoclastogenesis. NDGA also suppressed activation of ERK in osteoclast precursors. RANKL-induced calcium oscillation observed in osteoclast precursors was completely diminished by the addition of NDGA. In mature osteoclasts, RANKL-induced nuclear translocation of NFATc1 was clearly inhibited by NDGA treatment. Finally, in vivo studies demonstrated that administration of NDGA significantly reduced severe bone destruction and osteoclast recruitment in the ankle joint of rats with adjuvant-induced arthritis. These results indicate the potential utility of NDGA as a therapeutic agent for ameliorating inflammatory bone destruction in rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=84870465696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870465696&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2012.134

DO - 10.1038/labinvest.2012.134

M3 - Article

C2 - 23044922

AN - SCOPUS:84870465696

VL - 92

SP - 1777

EP - 1787

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 12

ER -